CL2012000478A1 - Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer. - Google Patents
Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer.Info
- Publication number
- CL2012000478A1 CL2012000478A1 CL2012000478A CL2012000478A CL2012000478A1 CL 2012000478 A1 CL2012000478 A1 CL 2012000478A1 CL 2012000478 A CL2012000478 A CL 2012000478A CL 2012000478 A CL2012000478 A CL 2012000478A CL 2012000478 A1 CL2012000478 A1 CL 2012000478A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- pharmaceutical composition
- cyclopenta
- pyrrolo
- carbazole
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 4-methyl-1-piperazinyl Chemical group 0.000 title 1
- AGFYXNWRDSDSRA-UHFFFAOYSA-N 6h-pyrrolo[3,4-c]carbazole-1,3-dione Chemical compound N1C2=CC=CC=C2C2=C1C=CC1=C2C(=O)NC1=O AGFYXNWRDSDSRA-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23718009P | 2009-08-26 | 2009-08-26 | |
| PCT/US2010/046671 WO2011028580A1 (en) | 2009-08-26 | 2010-08-25 | Novel forms of a multicyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000478A1 true CL2012000478A1 (es) | 2012-11-05 |
Family
ID=43033463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000478A CL2012000478A1 (es) | 2009-08-26 | 2012-02-24 | Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8633314B2 (enExample) |
| EP (1) | EP2470540B1 (enExample) |
| JP (3) | JP2013503173A (enExample) |
| KR (1) | KR20120092100A (enExample) |
| CN (1) | CN102482282A (enExample) |
| AU (1) | AU2010289746B2 (enExample) |
| BR (1) | BR112012004053A2 (enExample) |
| CA (1) | CA2772328C (enExample) |
| CL (1) | CL2012000478A1 (enExample) |
| DK (1) | DK2470540T3 (enExample) |
| EA (1) | EA020756B1 (enExample) |
| ES (1) | ES2572652T3 (enExample) |
| IL (1) | IL218132B (enExample) |
| MX (1) | MX2012002456A (enExample) |
| MY (1) | MY156873A (enExample) |
| NZ (1) | NZ598883A (enExample) |
| SG (1) | SG178852A1 (enExample) |
| UA (1) | UA110604C2 (enExample) |
| WO (1) | WO2011028580A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020756B1 (ru) * | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
| AU2015353549A1 (en) * | 2014-11-26 | 2017-06-01 | Cephalon, Inc. | Crystalline forms of PARP inhibitors |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| US20060276497A1 (en) | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| CA2620052A1 (en) * | 2005-08-24 | 2007-03-01 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
| CN101784268B (zh) * | 2006-11-20 | 2013-06-19 | 赛福伦公司 | 使用辐射敏化剂使肿瘤对辐射敏化的方法 |
| EA020756B1 (ru) * | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
-
2010
- 2010-08-25 EA EA201270315A patent/EA020756B1/ru not_active IP Right Cessation
- 2010-08-25 CA CA2772328A patent/CA2772328C/en not_active Expired - Fee Related
- 2010-08-25 MX MX2012002456A patent/MX2012002456A/es active IP Right Grant
- 2010-08-25 MY MYPI2012000710A patent/MY156873A/en unknown
- 2010-08-25 EP EP10750210.6A patent/EP2470540B1/en active Active
- 2010-08-25 WO PCT/US2010/046671 patent/WO2011028580A1/en not_active Ceased
- 2010-08-25 CN CN2010800380284A patent/CN102482282A/zh active Pending
- 2010-08-25 NZ NZ598883A patent/NZ598883A/en not_active IP Right Cessation
- 2010-08-25 UA UAA201203501A patent/UA110604C2/uk unknown
- 2010-08-25 DK DK10750210.6T patent/DK2470540T3/en active
- 2010-08-25 AU AU2010289746A patent/AU2010289746B2/en not_active Ceased
- 2010-08-25 BR BR112012004053-7A patent/BR112012004053A2/pt not_active IP Right Cessation
- 2010-08-25 ES ES10750210.6T patent/ES2572652T3/es active Active
- 2010-08-25 SG SG2012012290A patent/SG178852A1/en unknown
- 2010-08-25 JP JP2012526945A patent/JP2013503173A/ja active Pending
- 2010-08-25 KR KR1020127007524A patent/KR20120092100A/ko not_active Ceased
-
2012
- 2012-02-15 IL IL218132A patent/IL218132B/en not_active IP Right Cessation
- 2012-02-24 CL CL2012000478A patent/CL2012000478A1/es unknown
- 2012-02-24 US US13/404,137 patent/US8633314B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 JP JP2015151114A patent/JP2016014029A/ja not_active Ceased
-
2017
- 2017-09-04 JP JP2017169876A patent/JP2018035158A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011028580A1 (en) | 2011-03-10 |
| EA201270315A1 (ru) | 2012-08-30 |
| CA2772328A1 (en) | 2011-03-10 |
| JP2016014029A (ja) | 2016-01-28 |
| MY156873A (en) | 2016-04-15 |
| CN102482282A (zh) | 2012-05-30 |
| UA110604C2 (uk) | 2016-01-25 |
| AU2010289746A1 (en) | 2012-04-12 |
| KR20120092100A (ko) | 2012-08-20 |
| ES2572652T3 (es) | 2016-06-01 |
| AU2010289746B2 (en) | 2016-07-07 |
| JP2013503173A (ja) | 2013-01-31 |
| DK2470540T3 (en) | 2016-08-01 |
| EP2470540A1 (en) | 2012-07-04 |
| NZ598883A (en) | 2014-09-26 |
| EA020756B1 (ru) | 2015-01-30 |
| US20120214998A1 (en) | 2012-08-23 |
| US8633314B2 (en) | 2014-01-21 |
| BR112012004053A2 (pt) | 2020-12-08 |
| JP2018035158A (ja) | 2018-03-08 |
| EP2470540B1 (en) | 2016-04-20 |
| CA2772328C (en) | 2017-06-20 |
| MX2012002456A (es) | 2012-05-08 |
| IL218132A0 (en) | 2012-06-28 |
| HK1171750A1 (zh) | 2013-04-05 |
| IL218132B (en) | 2018-02-28 |
| SG178852A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008002687A1 (es) | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. | |
| CL2009000447A1 (es) | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| UY32049A (es) | Inhibidores de cmet | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| CL2008001862A1 (es) | Forma cristalina i, iii e hidratada de 6-{difluoro-[6-(1-metil-1h-pirazol-4-il)[1,2,4]triazolo[4,3-b]piridazin-3-il]metil}quinolina; composicion farmaceutica que las comprende; y su uso para prevenir o tratar un un trastorno proliferativo celular. | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| CL2011000917A1 (es) | Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias. | |
| PA8740901A1 (es) | Compuestos organicos | |
| GT201000008A (es) | Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico | |
| ECSP10010688A (es) | Activadores de glucoquinasa | |
| CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
| CL2010000320A1 (es) | Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2011000729A1 (es) | Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| MX388787B (es) | El uso de amisulpride como un anti-emético. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2012000478A1 (es) | Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer. | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. |